Healthcare / Drug Manufacturers - Specialty & GenericNSE
$434.45
+32.00 (+7.95%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 23%
FCF escenarios
weak_data · normalized FCF $744.9M · quality 49.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
66/100
B
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$46.0B
P/E
36.2x
↑EV/EBITDA
19.8x
↑ROE
10.8%
↑Gross Margin
54.2%
↑Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+7.4%
FCF CAGR
—
FCF margin
8.8%
FCF / Net income
0.63x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $9.27B · net income $1.29B · FCF $818.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $9.27B | $9.27B | $8.10B | $7.66B | $7.47B |
| Net Income | $1.29B | $1.29B | $843.0M | $754.5M | $708.6M |
| EBITDA | $2.35B | $2.35B | $1.63B | $1.49B | $1.28B |
| EPS | 12.00 | 12.00 | 7.95 | 7.11 | 6.72 |
| Gross Margin | 54.2% | 54.2% | 48.9% | 50.1% | 46.3% |
| Operating Margin | 14.1% | 14.1% | 12.0% | 17.6% | 13.5% |
| Net Margin | 13.9% | 13.9% | 10.4% | 9.9% | 9.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.08 | 0.10 | 0.12 |
| Cash Flow | |||||
| Free Cash Flow | $818.9M | $818.9M | $296.3M | $744.9M | $-594.9M |
| Returns | |||||
| ROE | 10.8% | 10.8% | 8.0% | 7.8% | 8.0% |
| Valuation | |||||
| P/E | 36.23 | 36.23 | 15.14 | 16.82 | 11.05 |
| EV/EBITDA | 19.83 | 19.83 | 8.22 | 9.04 | 6.72 |
| P/B | 3.92 | 3.92 | 1.22 | 1.31 | 0.89 |
| Growth & Yield | |||||
| Revenue Growth | 14.5% | 14.5% | 5.7% | 2.5% | — |
| EPS Growth | 50.9% | 50.9% | 11.8% | 5.8% | — |
| Dividend Yield | 0.3% | 0.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
47.6%
EPS terminal req.
$38.55
Spread vs growth
3.4%
5Y implied EPS CAGR
31.2%
EPS terminal req.
$46.65
Spread vs growth
19.7%
10Y implied EPS CAGR
20.1%
EPS terminal req.
$75.12
Spread vs growth
30.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+228.7%
Start / end P/E
16.6x → 36.2x
EPS bridge
7.95 → 12.00
Residual
+59.9%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.